Bristol Myers Squibb Company $BMY Shares Sold by World Investment Advisors

World Investment Advisors reduced its position in Bristol Myers Squibb Company (NYSE:BMY) by 7.1% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 54,673 shares of the biopharmaceutical company’s stock after selling 4,206 shares during the quarter. World Investment Advisors’ holdings in Bristol Myers Squibb were worth $2,531,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Brighton Jones LLC increased its position in Bristol Myers Squibb by 33.4% during the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after purchasing an additional 4,935 shares during the period. Rossby Financial LCC acquired a new position in Bristol Myers Squibb during the 1st quarter worth approximately $124,000. First Horizon Advisors Inc. increased its position in Bristol Myers Squibb by 9.8% during the 1st quarter. First Horizon Advisors Inc. now owns 446,375 shares of the biopharmaceutical company’s stock worth $27,224,000 after purchasing an additional 39,917 shares during the period. Resonant Capital Advisors LLC increased its position in Bristol Myers Squibb by 3.4% during the 1st quarter. Resonant Capital Advisors LLC now owns 51,231 shares of the biopharmaceutical company’s stock worth $3,125,000 after purchasing an additional 1,675 shares during the period. Finally, Mutual Advisors LLC increased its position in Bristol Myers Squibb by 24.4% during the 1st quarter. Mutual Advisors LLC now owns 68,897 shares of the biopharmaceutical company’s stock worth $4,202,000 after purchasing an additional 13,504 shares during the period. 76.41% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 56,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total value of $2,650,480.00. Following the sale, the executive vice president owned 167,379 shares of the company’s stock, valued at approximately $7,922,048.07. This represents a 25.07% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.09% of the company’s stock.

Bristol Myers Squibb Price Performance

BMY stock opened at $45.63 on Friday. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $63.33. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21. The stock’s 50 day moving average price is $45.37 and its 200 day moving average price is $46.86. The firm has a market cap of $92.88 billion, a P/E ratio of 18.40, a PEG ratio of 2.23 and a beta of 0.33.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.52 by $0.11. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The firm had revenue of $12.22 billion for the quarter, compared to analyst estimates of $11.75 billion. During the same quarter in the prior year, the company earned $1.80 EPS. Bristol Myers Squibb’s revenue was up 2.8% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. On average, sell-side analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, November 3rd. Investors of record on Friday, October 3rd will be paid a $0.62 dividend. The ex-dividend date of this dividend is Friday, October 3rd. This represents a $2.48 dividend on an annualized basis and a yield of 5.4%. Bristol Myers Squibb’s dividend payout ratio is presently 100.00%.

Analysts Set New Price Targets

Several equities analysts have issued reports on BMY shares. Daiwa America cut Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 5th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Bristol Myers Squibb in a research report on Tuesday, October 14th. Daiwa Capital Markets cut Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 target price on the stock. in a research report on Tuesday, August 5th. Citigroup restated a “neutral” rating on shares of Bristol Myers Squibb in a report on Monday, October 13th. Finally, Morgan Stanley restated a “hold” rating on shares of Bristol Myers Squibb in a report on Thursday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and fourteen have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $57.23.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.